These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Role of CRISPR/Cas9 in the treatment of Duchenne muscular dystrophy and its delivery strategies. Agrawal P; Harish V; Mohd S; Singh SK; Tewari D; Tatiparthi R; Harshita ; Vishwas S; Sutrapu S; Dua K; Gulati M Life Sci; 2023 Oct; 330():122003. PubMed ID: 37544379 [TBL] [Abstract][Full Text] [Related]
15. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles. Li S; Du M; Deng J; Deng G; Li J; Song Z; Han H Acta Biomater; 2022 Dec; 154():597-607. PubMed ID: 36243370 [TBL] [Abstract][Full Text] [Related]
16. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998 [TBL] [Abstract][Full Text] [Related]
17. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Aartsma-Rus A; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S71-7. PubMed ID: 12206800 [TBL] [Abstract][Full Text] [Related]
18. Molecular and Biochemical Assessment of Gene Therapy in the Canine Model of Duchenne Muscular Dystrophy. Hakim CH; Pérez-López D; Burke MJ; Teixeira J; Duan D Methods Mol Biol; 2023; 2587():255-301. PubMed ID: 36401035 [TBL] [Abstract][Full Text] [Related]
20. Contributions of Japanese patients to development of antisense therapy for DMD. Matsuo M; Takeshima Y; Nishio H Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]